Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, ...

The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio’s ...

Importantly, these exosomes were produced from NurExone’s proprietary master cell bank, whose cells are maintained under ...

Singapore, Singapore, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Heartland Physio is proud to unveil its signature R.E.A.L. Recovery™ ...

WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced an update on institutional ownership of the Company’s outstanding ...

The grants described in this press release were approved by the Compensation Committee of the Amwell’s Board of Directors pursuant to the Amwell’s Inducement Plan and made in reliance on the ...

Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain ...

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout ...

The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions ...

Patent Issuance: In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 by the U.S. Patent and Trademark Office, covering its SWAP™ technology for creating multi-specific Wnt surrogate molecules ...

The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...

Research and development expenses were $0.9 million for each of the three months ended June 30, 2025 and June 30, 2024, as an increase in EB06-related expenses for Edesa’s planned Phase 2 vitiligo ...